The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
Open Access
- 16 February 2012
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 106 (5), 858-866
- https://doi.org/10.1038/bjc.2012.8
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2Blood, 2011
- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced CancerClinical Cancer Research, 2010
- Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor–induced DNA damage in vitro and in vivo in human multiple myeloma cellsBlood, 2008
- B-RafV600E signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cellsOncogene, 2007
- ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xLThe EMBO Journal, 2007
- Irradiation-induced G2/M checkpoint response requires ERK1/2 activationOncogene, 2007
- Enhancement of the Therapeutic Efficacy of Taxol by the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 in Nude Mice Bearing Human HeterotransplantsCancer Research, 2005
- The MAP kinase pathway is required for entry into mitosis and cell survivalOncogene, 2004
- Nerve Growth Factor (NGF) Down-regulates the Bcl-2 Homology 3 (BH3) Domain-only Protein Bim and Suppresses Its Proapoptotic Activity by PhosphorylationJournal of Biological Chemistry, 2002
- Raf-1/MEK/MAPK Pathway Is Necessary for the G2/M Transition Induced by NocodazoleJournal of Biological Chemistry, 2000